1. Introduction {#sec1}
===============

Cardiovascular diseases (CVDs) are the most common cause of death in the world \[[@B1]\]. Every year more than 10 million human lives are lost because of CVDs, and the mortality is predicted to increase to 23.6 million by 2030 \[[@B2]\]. The underlying mechanisms of CVDs are extremely complicated and not fully revealed, leading to a challenge for CVDs treatment in modern medicine. With the progress of modern medicine, various allopathic medicines with significant curative effects have been reported in recent years. However, there are still some medical problems of CVDs not solved satisfactorily with current western allopathic therapy.

Traditional Chinese medicine (TCM) characterized by multiple compounds and targets has shown its marked effects on various human diseases. Successful applications of Chinese herbal have been reported for CVDs prevention and treatment. Wen-Dan Decoction is one of the notable examples. Wen-Dan Decoction is composed of six herbs, including*Arum ternatum* Thunb,*Zingiber officinale* Roscoe, Caulis Bambusae in Taenia, Aurantii Fructus Immaturus,*Citrus reticulata*, and licorice. This decoction has been used to treat CVDs since Tang Dynasty, and the clinical effects have been validated in previous research. Clinical studies show that Wen-Dan Decoction achieved notable success in treating coronary heart disease \[[@B3]\], hypertension \[[@B4]\], arrhythmia \[[@B5]\], and heart failure \[[@B6]\]. Although the effect of Wen-Dan Decoction on CVD is promising, its pharmacological actions have not been fully revealed.

By integrating systems biology and pharmacology, systems pharmacology provides a new approach to reveal the complicated mechanisms of TCM in treating complicated diseases through pharmacokinetic evaluation, target prediction, and network/pathway analysis \[[@B7], [@B8]\]. Here, we developed a system pharmacology approach to explore the molecular mechanisms of Wen-Dan Decoction in CVDs treatment. First, we built a molecular database for all 6 herbs in Wen-Dan Decoction and used ADME system to screen the active compounds based on the above database. Next, potential targets were predicted and drug-target interactions were further constructed. Then, we constructed the networks to illustrate the molecular mechanisms of Wen-Dan Decoction in CVDs treatment. Finally, pathway integration analysis was performed to uncover CVDs pathway and therapeutic modules of target proteins. We believed that the results will significantly improve our understanding of the underlying mechanisms of Wen-Dan Decoction and provide new evidence for clinical application of Wen-Dan Decoction in cardiovascular disease.

2. Methods {#sec2}
==========

The protocol of the systems pharmacology approach introduced in this work ([Figure 1](#fig1){ref-type="fig"}) includes 5 main steps as follows: (1) molecular database construction for all 6 herbs in Wen-Dan Decoction; (2) ADME evaluation to screen the active ingredients from the above compound database; (3) target-fishing to predict the direct targets of the obtained active compounds; (4) network construction and analysis to illustrate the molecular mechanism of Wen-Dan Decoction in treating CVDs; (5) pathway analysis to disclose CVDs pathway and therapeutic modules of target proteins.

2.1. Molecular Database Construction {#sec2.1}
------------------------------------

A total of 140 active compounds of 6 drugs in Wen-Dan Decoction were manually collected from previously developed molecular database: Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) \[[@B9]\].

2.2. ADME Evaluation {#sec2.2}
--------------------

An in silico integrative model-ADME (absorption, distribution, metabolism, and excretion of drugs) including PreOB (predicts oral bioavailability) and PreDL (predicts drug-likeness) was used to screen the potential active compounds from Wen-Dan Decoction.

Considering that OB is one of the most crucial pharmacokinetic properties of orally administered drugs which has been proven to be efficient in the drug delivery to the systemic circulation, we introduced a robust in-house model OBioavail1.1 \[[@B10]\] to predict the OB value for drugs. The compounds with OB ≥30% were screened out for further analysis.

Considering that DL of molecules is one of the important factors in the ADME of human body, a PreDL model was developed to calculate the DL values of each active compound through evaluating the Tanimoto similarity \[[@B11]\] between compounds and chemicals in the Drugbank Database \[[@B12]\]. The compounds with DL ≥0.18 were screened out for further analysis.

2.3. Target-Fishing {#sec2.3}
-------------------

Drug-targeting was firstly implemented by TCMSP Database and then an in-house model on the basis of ligand-target chemical genomics was introduced to enlarge the target library and increase the accuracy. We used Sys DT model which was developed on the basis of Random Forest (RF) and Support Vector Machine (SVM) algorithm to predict the target from potential active molecules of drugs. Only the targets with RF \> 0.7 and SVM \> 0.7 were reserved for further analysis.

To further explore functional annotation of the targets, a Gene Ontology Biological Process (GOBP) enrichment was performed through linking targets to DAVID \[[@B13]\] for classification. Only the terms with *P* value less than 0.05 were selected.

2.4. Network Construction {#sec2.4}
-------------------------

### 2.4.1. Compound-Target (C-T) Network {#sec2.4.1}

In this section, a compound-target network was built to illustrate drug-target interactions of all active compounds in Wen-Dan Decoction and their potential targets. In this network, compounds are linked with their targeted proteins.

### 2.4.2. Target-Disease (T-D) Network {#sec2.4.2}

To comprehensively understand the interrelationship between potential targets and diseases, a target-disease network linking target proteins with their relevant diseases and a target-CVDs (T-cD) network linking specific targets with CVDs were built by Cytoscape 2.8.1 \[[@B14]\], and the quantitative property "degree" of these networks was analyzed by Network Analysis plugin and CentiScaPe 1.2 of Cytoscape \[[@B15]\].

### 2.4.3. Target-Pathway (T-P) Network {#sec2.4.3}

A Target-Pathway network is constructed by mapping the target proteins to the KEGG pathway database. The bipartite graphs were constructed by Cytoscape version 2.8.3. The compounds, targets, and pathways are represented by nodes, and the interaction between two nodes is represented by an edge. Node size is proportional to its degree.

### 2.4.4. Pathway Constructions and Analysis {#sec2.4.4}

To explore the modulating specific pathways and the therapeutic feature of the active compounds on CVD treatment, pathways related to CVDs were picked out and assembled into a "CVDs pathway and therapeutic modules" under the pathological and clinical data.

3. Results {#sec3}
==========

3.1. Active Compounds Identification {#sec3.1}
------------------------------------

A total of 801 compounds were collected from the six herbs of Wen-Dan Decoction. As a result, 140 active compounds with OB ≥ 30% and DL ≥ 0.18 were obtained and 127 of 140 active compounds with drug targets were selected for further analysis (as displayed in [Table S1](#supplementary-material-1){ref-type="supplementary-material"}). The top 5 molecules in degree ranking were presented in [Table 1](#tab1){ref-type="table"}.

As shown in [Table S1](#supplementary-material-1){ref-type="supplementary-material"}, there are 6 active compounds shared by two or more herbs of Wen-Dan Decoction. For instance, beta-sitosterol, a common ingredient of*Arum ternatum* Thunb and*Zingiber officinale* Roscoe, has inhibitory effects on the expression of VCAM-1 and ICAM-1, which promote atherosclerosis by regulating the chronic inflammatory process \[[@B16]\]. Stigmasterol, in*Arum ternatum* Thunb and*Zingiber officinale* Roscoe, has been found effective in inhibiting Ang II-stimulated vascular smooth muscle proliferation, in association with ROS reduction, SOD and CAT enhancement, and increase of p53 protein \[[@B17]\].

3.2. Drug-Targeting and Functional Analysis {#sec3.2}
-------------------------------------------

2239 compound-target interactions were built between 127 compounds and 283 targets. The results showed that mostly compounds act on more than one target, and different compounds can have the same target. For instance, cavidine from*Arum ternatum* Thunb, stigmasterol, and beta-sitosterol from*Arum ternatum* Thunb and*Zingiber officinale* Roscoe, 6-methoxyaurapten from Aurantii Fructus, and medicarpin from licorice can interact with the same target CHRM3. Luteolin from Aurantii Fructus and quercetin from licorice can interact with the same target CDKN1A, which has effects on treatment of gastritis. Stigmasterol, beta-sitosterol, and coniferin from*Arum ternatum* Thunb and*Zingiber officinale* Roscoe and isosinensetin and sinensetin from Aurantii Fructus can interact with the same target ADRB2, which has effects on treatment of asthma.

In the subsequent GOBP enrichment analysis, we listed the top 20 significantly enriched GO terms (as displayed in [Figure 2](#fig2){ref-type="fig"}); the results showed that most of these targets are strongly correlated to inflammatory response, hormonal balance, and homeostasis, including response to drug, regulation of cell proliferation, blood vessel development, and multicellular organismal homeostasis.

3.3. Network Construction and Analysis {#sec3.3}
--------------------------------------

### 3.3.1. Compound-Target (C-T) Network and Analysis {#sec3.3.1}

As shown in [Figure 3](#fig3){ref-type="fig"}, a compound-target interaction was generated based on 410 nodes (127 potential compounds and 283 potential targets) and 2239 edges. The average degree number of targets per compound is 18.055. The top 5 molecules and the top 5 targets in degree ranking were presented in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}, respectively. Among those active compounds, MOL127 exhibits the highest degree (degree = 152), followed by MOL053 (degree = 63), MOL033 (degree = 56), and MOL050 (degree = 43), which indicated the multitarget properties of compounds. Among the candidate targets, ESR1 shows the highest degree (Degree = 141), followed by PGHS2 (degree = 103), CaM (degree = 86), and HSP90A (degree = 79), which demonstrated the potential therapeutic effect of Wen-Dan Decoction.

### 3.3.2. Target-Disease (T-D) Network and Analysis {#sec3.3.2}

To comprehensively understand the interrelationship between potential targets and diseases, a target-disease interaction was built as shown in [Figure 4](#fig4){ref-type="fig"}. The results showed that multitargets are interrelated to the same diseases. For example, CDKN1A, IL1B, and TP53 are associated with gastritis; MPP1, MPP3, MPP9, PLAT, and SERPINE1 are associated with gastric ulcer; ADRA2A, SLC6A2, and SLC6A4 are associated with gastrointestinal disease. HTR2C, CYP1B1, CYP19A1, ESR1, ESR2, PDR, and AR are found to be interrelated to hormonal disorders; ABCC1, NQO1, TIMP1, ADRB2, and ALOX5 are associated with asthma. The results also revealed that multidiseases have the same target. For example, MPP3 and MPP9 are associated not only with gastric ulcer, but also with COPD, preeclampsia, and coronary artery diseases. SLC6A2 and SLC6A4 are associated not only with gastrointestinal disease, but also with anorexia nervosa, acute anxiety, and autism.

To illustrate the interrelationship between specific targets and their correlated CVDs, a target-CVDs (T-cD) network was built as shown in [Figure 5](#fig5){ref-type="fig"}. The results showed that most targets related to more than one CVDs-associated disease and the shared targets might be the potential therapeutic targets in the treatment of CVDs. For example, NOS3, which plays an important role in regulation of nitric oxide production \[[@B18]\], is associated with coronary artery disease, myocardial infarct, congestive heart failure, stroke, and hypertension. As one of the highest incidences of CVDs, coronary artery disease links with more than 20 targets in this T-cD network, such as VCAM1 and ICAM1 (reported to increase in dysfunctional endothelial cells \[[@B19]\]), MMP9, MMP3, and MMP2 (being influencing factors in cardiac fibrosis \[[@B20]\]). Interleukin family was also predicted to be related to coronary artery disease, including IL 6, IL4, IL10, IL1A, and IL1B. All the results revealed the multitarget therapeutic efficiency of Wen-Dan Decoction in CVDs treatment.

### 3.3.3. Target-Pathway (T-P) Network and Analysis {#sec3.3.3}

As shown in [Table 3](#tab3){ref-type="table"}, 92 targets are mapped to 51 pathways. A Target-Pathway interaction was built based on 143 nodes (92 potential targets and 51 potential pathways) and 324 edges (as shown in [Figure 6](#fig6){ref-type="fig"}). The results showed an average degree of 3.54 per target and 5.45 per pathway. Several target proteins (19/92) are mapped to more than 5 pathways, demonstrating that these targets may intercede the interactions between different pathways. The results also showed that the targets of Wen-Dan Decoction are mainly involved in the biological process of cancer, apoptosis, cell cycle, and so on. In addition, the main pathways coregulated by multiple targets, such as Ca^2+^ signal pathway and arachidonic acid metabolism pathway, have been validated as common pathways in the treatment of cardiovascular disease and stomach illness.

### 3.3.4. Pathway Constructions and Analysis {#sec3.3.4}

In this section, a "CVDs pathway" was conducted based on the present cognition of CVDs pathology. As shown in [Figure 7](#fig7){ref-type="fig"}, this CVDs-associated pathway can be separated into two representative therapeutic modules (calcium signal pathway and vascular smooth muscle contraction), which reveal the underlying therapeutic effects of Wen-Dan Decoction.

Hypertension is one of independent risk factors for CVDs. The sustained high blood pressure may lead to the impairment of target organs, such as heart and kidney. Therefore, the therapies that can control blood pressure within the normal range are beneficial in the treatment of CVDs. As shown in [Figure 7](#fig7){ref-type="fig"}, therapeutic modules through the regulation of vascular smooth muscle contraction and calcium signal pathway are involved in the blood pressure regulation of Wen-Dan Decoction. For instance, norepinephrine signaling operates the function of vascular smooth muscle contraction through the regulation of some certain active compounds on their corresponding target proteins, including ADRA1, PKC, Raf, and ERK. Neurotransmitter GPCR and its downstream signal pathway are involved in the regulation of CAMK activity, which may cause cardiac hypertrophy and myocardial dysfunction \[[@B21]\]. All the results indicated that the blood pressure associate pathway is a potent therapeutic target of Wen-Dan Decoction in CVDs treatment.

4. Discussion {#sec4}
=============

Cardiovascular disease remains the leading cause of human death around the world \[[@B22]\]. There are still some medical problems of CVDs not solved satisfactorily with current western allopathic therapy. The world is calling for a more efficient curative system. TCM is attracting more and more attention across the world for its marked effects in clinical practice. Wen-Dan Decoction, a clinically effective herb formula, has been used to treat CVDs specially accompanied by symptoms such as angina and arrhythmia. There is growing evidence showing that herbs and their active compounds in this decoction have biological effects on CVDs. For instance, Wen-Dan Decoction has been proven to regulate the disorder of lipid metabolism by raising the activity of total lipase (LA) and lipoprotein lipase (LPL) in the modal rats \[[@B23]\]. The elements of Wen-Dan Decoction and their active compounds, such as ginger \[[@B24], [@B25]\], Caulis Bambusae in Taenia \[[@B26]\], and licorice \[[@B27]\], also have been reported to attenuate the development of atherosclerotic lesions associated with a significant antihyperlipidemic effect. Besides, Wen-Dan Decoction can reverse hypertensive myocardial fibrosis and significantly reduce Ang II, ALDO in myocardial tissue, and plasma of SHR rats. The underlying mechanism may be related to the inhibition of the expression of TGF-beta 1, IGF 1, JNK, p38MAPK, and ERK5 in myocardial tissue \[[@B28], [@B29]\]. Citrus Reticulata and licorice exert cardioprotection by oxidative stress reduction, endogenous antioxidants augment, and structural integrity maintenance \[[@B30], [@B31]\]. However, the underlying mechanisms of action on the protein and pathway level are still unrevealed. Therefore, in this study, we developed a systems pharmacology approach to explore the mechanisms of Wen-Dan Decoction in CVDs treatment from a molecule to system level.

Previous studies suggested that TCM therapy has better influence on the complicated balance of whole cellular networks due to acting on multiple targets. The success examples of multitarget and combinatorial therapies indicated that systematic drug-design strategies should be directed against multiple targets \[[@B32]\]. In our work, a total of 801 compounds were collected from the six herbs of Wen-Dan Decoction. There are 6 active compounds shared by two or more herbs. 127 potential active compounds and their corresponding 283 direct targets were identified by ADME screening, demonstrating a multidrug-multitarget paradigm of Wen-Dan Decoction. Then, TCMSP Database and an in-house model on the basis of ligand-target chemical genomics were applied to conduct the drug-target interactions followed by GOBP analysis. 2239 compound-target interactions were found between 127 compounds and 283 targets. The analytical results distinctly revealed the action mode and biological processes that drugs utilized to achieve their curative effects. Finally, the networks were built for analysis to illustrate the molecular mechanism of Wen-Dan Decoction in CVDs treatment, and pathway analysis was performed to further dissect the therapeutic polypharmacology of Wen-Dan Decoction.

The underlying mechanisms of CVDs are extremely complicated and not fully revealed. We can tell from the results of this work that with multidrug-target-disease interactions active compounds of Wen-Dan Decoction achieve the curative results on CVDs treatment by regulating multiple targets and pathways. Since modern medicine is unable to prevent the medical failures and some ill-effects in CVDs treatment, TCM seems to be an alternative choice which shows great potential in confronting complex diseases.

5. Conclusion {#sec5}
=============

In the present study, a systems pharmacology approach was developed by integrating the ADME screening, targets prediction, network, and pathway analysis to uncover the underlying mechanisms of Wen-Dan Decoction. Our results showed the following:

\(1\) 127 potential active compounds and their corresponding 283 direct targets were identified in Wen-Dan Decoction, demonstrating a multidrug-multitarget paradigm.

\(2\) In drug-targeting and functional analysis, 2239 compound-target interactions were found between 127 compounds and 283 targets, indicating that most compounds of Wen-Dan Decoction act on more than one target, and different compounds can have the same target.

\(3\) In network analysis, the C-T network indicated the multitarget properties of compounds, being the essence of the action mode of Wen-Dan Decoction. The T-D network showed that multitargets are interrelated to the same diseases and also revealed that multidiseases have the same target. The T-P network and CVDs pathway displayed that targets of Wen-Dan Decoction may intercede the interactions between different pathways, which further demonstrated the two therapeutic modules of Wen-Dan Decoction in CVDs treatment: calcium signal pathway and vascular smooth muscle contraction.

\(4\) This work provides a new approach for understanding the underlying mechanisms of Wen-Dan Decoction and new evidence for clinical application of Wen-Dan Decoction in cardiovascular disease.
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Supplementary Materials {#supplementary-material-1}
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###### 

Table S1: chemical information of the 127 active compounds which were collected from the six herbs of Wen-Dan Decoction, such as molecule name, OB(%), BBB, Caco-2, DL, degree, structure, and herb name.

###### 

Click here for additional data file.

![Systems pharmacology approach workflow.](ECAM2018-5170854.001){#fig1}

![*Gene Ontology (GO) analysis*. The *y*-axis shows significantly enriched "biological process" categories in GO, and the *x*-axis shows the enrichment scores of those terms (*P* \< 0.05).](ECAM2018-5170854.002){#fig2}

![*C-T network*. Compounds are linked with their targeted proteins. Node size is proportional to its degree.](ECAM2018-5170854.003){#fig3}

![*T-D network*. Target proteins are linked with their correlated diseases and those diseases are linked with their correlated disease categories.](ECAM2018-5170854.004){#fig4}

![*Target-CVDs (T-cD) network*. Specific target proteins are linked with their correlated CVDs and CVDs are linked with their correlated disease categories.](ECAM2018-5170854.005){#fig5}

![*T-P network*. The Target-Pathway network is constructed by mapping the target proteins to the KEGG pathway database. Node size is proportional to its degree.](ECAM2018-5170854.006){#fig6}

![*CVDs pathway and therapeutic modules*. Distribution of target proteins of Wen-Dan Decoction on "CVDs pathway." Arrows represent activation effect, and T-arrows represent inhibition effect.](ECAM2018-5170854.007){#fig7}

###### 

Top 5 molecules in degree ranking.

  MOL ID   Molecule name                   Degree   Herb
  -------- ------------------------------- -------- ------------------------------------------------------
  MOL127   Quercetin                       152      Licorice
  MOL053   Kaempferol                      63       Licorice
  MOL033   Luteolin                        56       Aurantii Fructus Immaturus
  MOL050   7-Methoxy-2-methyl isoflavone   43       Licorice
  MOL004   beta-Sitosterol                 41       *Arum ternatum* Thunb & *Zingiber officinale* Roscoe

###### 

Top 5 targets in degree ranking.

  Target name   Degree
  ------------- --------
  ESR1          141
  PGHS2         103
  CaM           86
  HSP90A        79
  AR            75

###### 

Pathway and target interaction.

  Pathway                                                        Target
  -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathways in cancer                                             E2F1, E2F2, PPARD, PTGS2, MMP9, PPARG, PTEN, MMP2, TGFB1, MMP1, AKT1, FOS, CASP3, CASP9, CASP8, NOS2, MYC, CHUK, PRKCA, EGFR, PIK3CG, AR, RXRB, RELA, RXRA, RUNX1T1, TP53, RB1, CDK2, MAPK1, CCND1, HIF1A, JUN, MAPK3, VEGFA, MDM2, MAPK8, ERBB2, EGLN1, BCL2L1, BCL2, NKX3-1, EGF, IL6, MET, RAF1, BIRC5, MAPK10, STAT1, STAT3, CDKN1A, GSK3B, RASSF1, BAX, IKBKB
  Non-small cell lung cancer                                     PRKCA, E2F1, EGFR, PIK3CG, E2F2, RXRB, RXRA, ERBB2, TP53, RAF1, RB1, AKT1, MAPK1, CCND1, CASP9, RASSF1, MAPK3, EGF
  Colorectal cancer                                              EGFR, PIK3CG, MET, TP53, RAF1, BIRC5, MAPK10, TGFB1, AKT1, MAPK1, FOS, CASP3, CCND1, CASP9, GSK3B, JUN, BAX, BCL2, MAPK3, MAPK8, MYC
  Small cell lung cancer                                         E2F1, PIK3CG, E2F2, PTGS2, RXRB, RXRA, RELA, TP53, RB1, BCL2L1, PTEN, CDK2, AKT1, CCND1, CASP9, BCL2, NOS2, IKBKB, MYC, CHUK
  Toll-like receptor signaling pathway                           PIK3CG, IL6, TNF, RELA, MAPK10, CXCL11, STAT1, CXCL10, AKT1, MAPK1, FOS, MAPK14, JUN, MAPK3, CASP8, IL1B, MAPK8, IKBKB, CHUK, SPP1
  VEGF signaling pathway                                         PRKCA, PIK3CG, PTGS2, RAF1, KDR, AKT1, MAPK1, PLA2G4A, CASP9, MAPK14, VEGFA, MAPK3, HSPB1, NOS3, PPP3CA, PLA2G2E, NFATC1
  T cell receptor signaling pathway                              IL4, PIK3CG, TNF, RELA, RAF1, IL10, AKT1, MAPK1, FOS, CD40LG, MAPK14, GSK3B, JUN, IFNG, MAPK3, PPP3CA, IKBKB, CHUK, NFATC1, IL2
  Apoptosis                                                      PIK3CG, TNF, RELA, TP53, BCL2L1, AKT1, CASP3, CASP9, BAX, CASP7, BCL2, CASP8, IL1B, PRKACA, PPP3CA, IKBKB, CHUK, IL1A
  ErbB signaling pathway                                         PRKCA, EGFR, PIK3CG, ERBB3, ERBB2, RAF1, ELK1, MAPK10, AKT1, MAPK1, CDKN1A, GSK3B, JUN, MAPK3, MAPK8, EGF, MYC
  Insulin signaling pathway                                      SREBF1, PIK3CG, HK2, ACACA, RAF1, ELK1, PDE3A, IGF2, MAPK10, AKT1, MAPK1, SLC2A4, PYGM, GSK3B, MAPK3, FASN, MAPK8, PRKACA, PTPN1, IKBKB, INSR
  p53 signaling pathway                                          TP53, CHEK1, CHEK2, PTEN, CDK2, CCNB1, CDKN1A, CASP3, CCND1, CASP9, BAX, CASP8, SERPINE1, MDM2, IGFBP3
  NOD-like receptor signaling pathway                            IL6, CCL2, TNF, RELA, CXCL2, MAPK10, MAPK1, MAPK14, MAPK3, CASP8, IL1B, MAPK8, IKBKB, CHUK
  Progesterone-mediated oocyte maturation                        PIK3CG, ADCY2, RAF1, PDE3A, IGF2, MAPK10, CDK2, AKT1, CCNB1, PGR, MAPK1, MAPK14, MAPK3, PRKACA, MAPK8, CCNA2
  MAPK signaling pathway                                         TNF, ELK1, TGFB1, AKT1, FOS, CASP3, IL1B, PRKACA, PPP3CA, EGF, MYC, CHUK, IL1A, RASA1, EGFR, PRKCA, RELA, TP53, RAF1, MAPK10, MAPK1, PLA2G4A, MAPK14, JUN, MAPK3, HSPB1, MAPK8, PLA2G2E, IKBKB
  Focal adhesion                                                 PRKCA, EGFR, PIK3CG, CAV1, ERBB2, MET, COL3A1, ELK1, RAF1, MAPK10, PTEN, KDR, AKT1, MAPK1, CCND1, GSK3B, JUN, BCL2, VEGFA, MAPK3, MAPK8, COL1A1, EGF, SPP1
  Calcium signaling pathway                                      PRKCA, EGFR, PIK3CG, CAV1, ERBB2, MET, COL3A1, ELK1, RAF1, MAPK10, PTEN, KDR, AKT1, MAPK1, CCND1, GSK3B, JUN, BCL2, VEGFA, MAPK3, MAPK8, COL1A1, EGF, SPP1PRKCA, EGFR, DRD1, ADCY2, PTGER3, ERBB3, ERBB2, CHRM5, ADRB2, ADRB1, CHRM3, CHRM2, CHRM1, ADRA1B, ADRA1A, NOS3, CHRNA7, PRKACA, PPP3CA, NOS2, HTR2C, ADRA1D, HTR2A
  GnRH signaling pathway                                         PRKCA, EGFR, ADCY2, RAF1, ELK1, MAPK10, MMP2, PRKCD, MAPK1, PLA2G4A, MAPK14, JUN, MAPK3, PRKACA, MAPK8, PLA2G2E
  Fc epsilon RI signaling pathway                                PRKCA, IL4, PIK3CG, TNF, RAF1, MAPK10, PRKCD, AKT1, MAPK1, PLA2G4A, MAPK14, MAPK3, MAPK8, PLA2G2E
  Adipocytokine signaling pathway                                PPARA, TNF, RXRB, RXRA, RELA, MAPK10, ADIPOQ, STAT3, AKT1, SLC2A4, MAPK8, IKBKB, CHUK
  B cell receptor signaling pathway                              PIK3CG, AKT1, MAPK1, FOS, RELA, JUN, GSK3B, MAPK3, RAF1, PPP3CA, IKBKB, CHUK, NFATC1
  Steroid hormone biosynthesis                                   AKR1C3, CYP3A4, HSD3B2, CYP1B1, HSD3B1, CYP1A1, SULT1E1, UGT1A1, AKR1C1, CYP19A1
  Neurotrophin signaling pathway                                 PIK3CG, RELA, TP53, RAF1, MAPK10, PRKCD, AKT1, MAPK1, MAPK14, GSK3B, JUN, BAX, BCL2, MAPK3, MAPK8, IKBKB
  Cell cycle                                                     E2F1, E2F2, TP53, CHEK1, RB1, CHEK2, TGFB1, CDK2, CCNB1, CCND1, CDKN1A, GSK3B, PCNA, MDM2, MYC, CCNA2
  Chemokine signaling pathway                                    PIK3CG, ADCY2, CCL2, NCF1, RELA, CXCL2, RAF1, STAT1, CCL16, CXCL11, PRKCD, STAT3, CXCL10, AKT1, MAPK1, GSK3B, MAPK3, PRKACA, IKBKB, CHUK
  Neuroactive ligand-receptor interaction                        OPRM1, DRD1, GABRA2, GABRA1, PTGER3, GABRA3, GABRA5, PRSS1, CHRM5, ADRB2, ADRB1, CHRM4, CHRM3, GRIA2, CHRM2, CHRM1, F2, ADRA1B, ADRA2A, ADRA1A, ADRA2C, HTR2C, ADRA1D, HTR2A, OPRD1
  Gap junction                                                   PRKCA, EGFR, DRD1, ADCY2, GJA1, RAF1, MAPK1, ADRB1, MAPK3, PRKACA, EGF, HTR2C, HTR2A
  Metabolism of xenobiotics by cytochrome P450                   GSTM1, AKR1C3, CYP3A4, GSTM2, CYP1B1, CYP1A1, ADH1C, CYP1A2, UGT1A1, AKR1C1
  Epithelial cell signaling in *Helicobacter pylori* infection   EGFR, CASP3, RELA, MAPK14, JUN, MET, MAPK8, MAPK10, IKBKB, CHUK
  Vascular smooth muscle contraction                             PRKCA, KCNMA1, MAPK1, PLA2G4A, ADCY2, MAPK3, ADRA1B, ADRA1A, RAF1, PRKACA, PLA2G2E, PRKCD, ADRA1D
  Arachidonic acid metabolism                                    AKR1C3, PLA2G4A, PTGS2, PTGES, PTGS1, LTA4H, ALOX5, PLA2G2E, ALOX12
  PPAR signaling pathway                                         PPARA, PPARD, OLR1, RXRB, RXRA, PPARG, ADIPOQ, MMP1, FABP5
  RIG-I-like receptor signaling pathway                          TNF, RELA, MAPK14, CASP8, MAPK8, MAPK10, IKBKB, CHUK, CXCL10
  Cytokine-cytokine receptor interaction                         EGFR, IL4, IL6, TNF, CCL2, MET, CXCL2, CCL16, CXCL11, IL10, TGFB1, CXCL10, KDR, CD40LG, VEGFA, IFNG, IL1B, EGF, IL1A, IL2
  Drug metabolism                                                GSTM1, CYP3A4, GSTM2, MAOA, MAOB, ADH1C, CYP1A2, UGT1A1
  Wnt signaling pathway                                          PRKCA, CCND1, PPARD, GSK3B, JUN, TP53, MAPK8, PRKACA, PPP3CA, MAPK10, MYC, FOSL1, NFATC1
  mTOR signaling pathway                                         PIK3CG, AKT1, MAPK1, HIF1A, MAPK3, VEGFA, IGF2
  Complement and coagulation cascades                            PLAT, F10, THBD, F3, F2, SERPINE1, F7, PLAU
  Jak-STAT signaling pathway                                     PIK3CG, IL4, AKT1, IL6, CCND1, IFNG, PIM1, BCL2L1, STAT1, MYC, IL10, STAT3, IL2
  Tryptophan metabolism                                          CYP1B1, CYP1A1, MAOA, MAOB, CYP1A2, CAT
  Aldosterone-regulated sodium reabsorption                      PRKCA, PIK3CG, MAPK1, MAPK3, IGF2, INSR
  Oocyte meiosis                                                 CCNB1, PGR, MAPK1, AR, ADCY2, MAPK3, IGF2, PRKACA, PPP3CA, CDK2
  Fc gamma R-mediated phagocytosis                               PRKCA, PIK3CG, AKT1, MAPK1, PLA2G4A, NCF1, MAPK3, RAF1, PRKCD
  Natural killer cell mediated cytotoxicity                      PRKCA, PIK3CG, ICAM1, MAPK1, CASP3, TNF, MAPK3, IFNG, RAF1, PPP3CA, NFATC1
  Intestinal immune network for IgA production                   IL4, IL6, CD40LG, IL10, TGFB1, IL2
  Long-term depression                                           PRKCA, MAPK1, PLA2G4A, GRIA2, MAPK3, RAF1, PLA2G2E
  Androgen and estrogen metabolism                               HSD3B2, HSD3B1, SULT1E1, UGT1A1, CYP19A1
  Arginine and proline metabolism                                ODC1, GOT1, MAOA, MAOB, NOS3, NOS2
  Cytosolic DNA-sensing pathway                                  IL6, RELA, IL1B, IKBKB, CHUK, CXCL10
  Adherens junction                                              EGFR, MAPK1, ERBB2, MET, MAPK3, PTPN1, INSR
  Leukocyte transendothelial migration                           PRKCA, PIK3CG, VCAM1, ICAM1, CLDN4, NCF1, MAPK14, MMP9, MMP2
  Tyrosine metabolism                                            TYR, GOT1, MAOA, MAOB, ADH1C
  Linoleic acid metabolism                                       CYP3A4, PLA2G4A, CYP1A2, PLA2G2E

[^1]: Academic Editor: Carmen Mannucci
